New Drug-Free Option for Migraine Prevention: Remote Electrical Neuromodulation
Understanding the Impact of Migraines
Recent research has revealed a promising drug-free approach to migraine prevention known as remote electrical neuromodulation (REN). Migraines affect approximately 14% of the global population, translating to over one billion individuals worldwide. Unfortunately, many cases remain underdiagnosed and inadequately treated. While various medications exist to manage migraine symptoms post-attack, they do not work for everyone. This underscores the importance of clinical research focused on migraine prevention.
Migraines are not only painful but can also severely disrupt both professional and social lives. Moreover, they may lead to long-term health issues, including an increased risk of stroke, heart conditions, anxiety, depression, and sleep disorders.
Defining a Migraine
A migraine is more than just an intense headache; it is a debilitating headache disorder characterized by:
– Throbbing pain often localized to one side of the head
– Moderate to severe pain intensity
– Duration ranging from 4 to 72 hours
– Exacerbation of pain through even light physical activity
Additionally, common symptoms can include nausea, vomiting, and heightened sensitivity to light and sound.
Types of Migraines
Migraines can be categorized into two primary types: with aura and without aura. An aura serves as a temporary sensory disturbance that can signal an impending migraine attack. It may also occur during the attack itself, manifesting as:
– Visual changes (e.g., blurred vision, blind spots, flashing lights, or zig-zag patterns)
– Speech or comprehension difficulties
– Numbness or tingling in various body parts
– Dizziness or balance issues
Current Treatment Approaches
During a migraine episode, individuals typically resort to over-the-counter pain relievers like acetaminophen or ibuprofen. If these medications prove ineffective, a consultation with a healthcare provider is often the next step.
Doctors may prescribe migraine-specific medications, non-specific medications, or a combination of both. Commonly recommended medications include:
**Migraine-Specific Medications:**
– Triptans (e.g., sumatriptan, eletriptan, zolmitriptan)
– Gepants (e.g., rimegepant, ubrogepant)
– Ergotamines (e.g., dihydroergotamine)
**Non-Specific Medications:**
– Anti-nausea medications (e.g., prochlorperazine)
– Anti-seizure medications (e.g., topiramate, valproate)
– Beta-blockers (e.g., propranolol, atenolol, metoprolol)
– Antidepressants (e.g., amitriptyline, duloxetine)
However, these medications can lead to undesirable side effects and may interact with other drugs. Additionally, some individuals are unable to use them due to pre-existing health conditions. The cost of migraine-specific medications can also be prohibitive, which is why alternative preventive methods such as REN are gaining attention.
Introducing Remote Electrical Neuromodulation (REN)
Remote electrical neuromodulation (REN) is a technique that employs electrodes to activate the body’s natural pain management system, thereby influencing pain signal transmission. The FDA-approved REN device, Nerivio, is worn on the arm and operated via a mobile app. It gently stimulates nerves in the upper arm, aiming to reduce pain signals to the head. Researchers hypothesize that consistent use of REN could enhance the body’s ability to manage pain and prevent migraines.
Details of the REN Clinical Trial
Participants in the clinical trial included individuals with either migraines with aura or without aura. One group was provided with the actual REN device, while the other received a placebo version. Neither the participants nor the researchers knew who had the real device until the study concluded.
Throughout the 16-month trial, participants wore their REN devices for 45 minutes every two days and recorded their experiences in nightly questionnaires. During migraine attacks, they could not use the device but were allowed to utilize other conventional treatments.
At the conclusion of the study, those using the real REN device experienced an average decrease of four migraine days per month, compared to only 1.3 days in the placebo group. Additionally, the REN group reported lower pain levels and a reduced need for medication during acute migraine episodes.
Implications for Migraine Management
Migraines pose a significant challenge for many individuals globally, affecting various aspects of life. The introduction of remote electrical neuromodulation (REN) may provide an effective option for migraine prevention. With a simple device controlled via a mobile app, individuals may gain better management over their migraines, rely less on medications, and potentially enhance their overall quality of life.
References
1. Tepper SJ, Rabany L, Cowan RP, et al. Remote electrical neuromodulation for migraine prevention: A double-blind, randomized, placebo-controlled clinical trial. Headache. 2023;63:377-389. doi: 10.1111/head.14469
2. The global prevalence of headache: an update, with analysis of the influences of methodological factors on prevalence estimates. J Headache and Pain. 2022;23(1). https://doi.org/10.1186/s10194-022-01402-2
3. Buse DC, Reed ML, Fanning KM, et al. Comorbid and co-occurring conditions in migraine and associated risk of increasing headache pain intensity and headache frequency: results of the migraine in America symptoms and treatment (MAST) study. J Headache Pain. 2020;21(1):23. https://doi.org/10.1186/s10194-020-1084-y
4. The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia. 2013;33(9):629-808. doi:10.1177/0333102413485658
5. Sinclair AJ, Sturrock A, Davies B, Matharu M. Headache management: Pharmacological approaches. Pract Neurol. 2015;15(6):411-423. doi:10.1136/practneurol-2015-001167
6. VanderPluym JH, Halker Singh RB, Urtecho M, et al. Acute treatments for episodic migraine in adults: A systematic review and meta-analysis. JAMA. 2021;325(23):2357–2369. doi:10.1001/jama.2021.7939